Serum response factor controls CYLD expression via MAPK signaling pathway

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Liang, Gang ^a   Ahlqvist, Kristofer ^a   Pannem, Rajeswararao ^a   Posern, Guido ^b   Massoumi, Ramin ^a  

^a LUND UNIVERSITY   (Sweden)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN CYLD; SERUM RESPONSE FACTOR; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CYLD PROTEIN, MOUSE; CYSTEINE PROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; EMBRYO; ENZYME BLOOD LEVEL; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; HOMEOSTASIS; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN BINDING; SERUM RESPONSIVE ELEMENT; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANIMAL EMBRYO; APOPTOSIS; CELL CULTURE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FIBROBLAST; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; SERUM;

ANIMALS; APOPTOSIS; BASE SEQUENCE; CELL PROLIFERATION; CELLS, CULTURED; CYSTEINE ENDOPEPTIDASES; EMBRYO, MAMMALIAN; FIBROBLASTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MAP KINASE SIGNALING SYSTEM; MICE; MOLECULAR SEQUENCE DATA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; SERUM; SERUM RESPONSE FACTOR; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955832514     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019613     Document Type: Article

References (49)

1. Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, et al. (2000) Identification of the familial cylindromatosis tumour-suppressor gene. Nature Genetics 25: 160-165.
2. Massoumi R, Kuphal S, Hellerbrand C, Haas B, Wild P, et al. (2009) Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. Journal of Experimental Medicine 206: 221-232.
3. Hirai Y, Kawamata Y, Takeshima N, Furuta R, Kitagawa T, et al. (2004) Conventional and array-based comparative genomic hybridization analyses of novel cell lines harboring HPV18 from glassy cell carcinoma of the uterine cervix. International Journal of Oncology 24: 977-986.
4. Hellerbrand C, Bumes E, Bataille F, Dietmaier W, Massoumi R, et al. (2007) Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis 28: 21-27.
5. Costello CM, Mah N, Hasler R, Rosenstiel P, Waetzig GH, et al. (2005) Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. Plos Medicine 2: 771-787.
6. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, et al. (2007) Frequent engagement of the classical and alternative NF-kappa B pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115-130.
7. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, et al. (2007) Promiscuous mutations activate the noncanonical NF-kappa B pathway in multiple myeloma. Cancer Cell 12: 131-144.
8. Massoumi R, Paus R, (2007) Cylindromatosis and the CYLD gene: new lessons on the molecular principles of epithelial growth control. Bioessays 29: 1203-1214.
9. Massoumi R Ubiquitin chain cleavage: CYLD at work. Trends Biochem Sci 35: 392-399.
10. Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R, (2006) Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappa B signaling. Cell 125: 665-677.
11. Reiley W, Zhang MY, Wu XF, Granger E, Sun SC, (2005) Regulation of the deubiquitinating enzyme CYLD by I kappa B kinase gamma-dependent phosphorylation. Molecular and Cellular Biology 25: 3886-3895.
12. Hutti JE, Shen RR, Abbott DW, Zhou AY, Sprott KM, et al. (2009) Phosphorylation of the Tumor Suppressor CYLD by the Breast Cancer Oncogene IKK epsilon Promotes Cell Transformation. Molecular Cell 34: 461-472.
13. An J, Mo D, Liu H, Veena MS, Srivatsan ES, et al. (2008) Inactivation of the CYLD Deubiquitinase by HPV E6 Mediates Hypoxia-Induced NF-kappa B Activation. Cancer Cell 14: 394-407.
14. Norman C, Runswick M, Pollock R, Treisman R, (1988) Isolation and Properties of Cdna Clones Encoding Srf, a Transcription Factor That Binds to the C-Fos Serum Response Element. Cell 55: 989-1003.
15. Sun Q, Chen G, Streb JW, Long XC, Yang YM, et al. (2006) Defining the mammalian CArGome. Genome Research 16: 197-207.
16. Treisman R, (1986) Identification of a Protein-Binding Site That Mediates Transcriptional Response of the C-Fos Gene to Serum Factors. Cell 46: 567-574.
17. Posern G, Treisman R, (2006) Actin' together: serum response factor, its cofactors and the link to signal transduction. Trends in Cell Biology 16: 588-596.
18. Miralles F, Posern G, Zaromytidou AI, Treisman R, (2003) Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell 113: 329-342.
19. Milyavsky M, Shats I, Cholostoy A, Brosh R, Buganim Y, et al. (2007) Inactivation of myocardin and p16 during malignant transformation contributes to a differentiation defect. Cancer Cell 11: 133-146.
20. Descot A, Rex-Haffner M, Courtois G, Bluteau D, Menssen A, et al. (2008) OTT-MAL is a deregulated activator of serum response factor-dependent gene expression. Mol Cell Biol 28: 6171-6181.
21. Descot A, Hoffmann R, Shaposhnikov D, Reschke M, Ullrich A, et al. (2009) Negative regulation of the EGFR-MAPK cascade by actin-MAL-mediated Mig6/Errfi-1 induction. Mol Cell 35: 291-304.
22. Rivera VM, Miranti CK, Misra RP, Ginty DD, Chen RH, et al. (1993) A growth factor-induced kinase phosphorylates the serum response factor at a site that regulates its DNA-binding activity. Mol Cell Biol 13: 6260-6273.
23. Miranti CK, Ginty DD, Huang G, Chatila T, Greenberg ME, (1995) Calcium Activates Serum Response Factor-Dependent Transcription by a Ras-Independent and Elk-1-Independent Mechanism That Involves a Ca2(+)/Calmodulin-Dependent Kinase. Molecular and Cellular Biology 15: 3672-3684.
24. Janknecht R, Hipskind RA, Houthaeve T, Nordheim A, Stunnenberg HG, (1992) Identification of multiple SRF N-terminal phosphorylation sites affecting DNA binding properties. Embo J 11: 1045-1054.
25. Marais RM, Hsuan JJ, McGuigan C, Wynne J, Treisman R, (1992) Casein kinase II phosphorylation increases the rate of serum response factor-binding site exchange. Embo J 11: 97-105.
26. Massoumi R, Kuphal S, Hellerbrand C, Haas B, Wild P, et al. (2009) Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med 206: 221-232.
27. Brummelkamp TR, Nijman SMB, Dirac AMG, Bernards R, (2003) Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappa B. Nature 424: 797-801.
28. Regamey A, Hohl D, Liu JW, Roger T, Kogerman P, et al. (2003) The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappa B activation by tumor necrosis factor. Journal of Experimental Medicine 198: 1959-1964.
29. Hill CS, Treisman R, (1995) Differential activation of c-fos promoter elements by serum, lysophosphatidic acid, G proteins and polypeptide growth factors. EMBO J 14: 5037-5047.
30. Johansen FE, Prywes R, (1995) Serum Response Factor- Transcriptional Regulation of Genes Induced by Growth-Factors and Differentiation. Biochimica Et Biophysica Acta-Reviews on Cancer 1242: 1-10.
31. Sara A, Wickström KCM, Saadi Khochbin, Reinhard Fässler, Ramin Massoumi, (2009) CYLD negatively regulates cell cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. EMBO Journal.
32. Yoshida H, Jono H, Kai H, Li JD, (2005) The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 and TRAF7. Journal of Biological Chemistry 280: 41111-41121.
33. Lim JH, Stirling B, Derry J, Koga T, Jono H, et al. (2007) Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity 27: 349-360.
34. Koga T, Lim JH, Jono H, Ha UH, Xu HD, et al. (2008) Tumor suppressor cylindromatosis acts as a negative regulator for Streptococcus pneumoniae-induced NFAT signaling. Journal of Biological Chemistry 283: 12546-12554.
35. Reiley W, Zhang MY, Sun SC, (2004) Negative regulation of JNK signaling by the tumor suppressor CYLD. Journal of Biological Chemistry 279: 55161-55167.
36. Xue L, Igaki T, Kuranaga E, Kanda H, Miura M, et al. (2007) Tumor suppressor CYLD regulates JNK-Induced cell death in Drosophila. Developmental Cell 13: 446-454.
37. Hahn WC, Weinberg RA, (2002) Modelling the molecular circuitry of cancer. Nature Reviews Cancer 2: 331-341.
38. Gauthierrouviere C, Cavadore JC, Blanchard JM, Lamb NJC, Fernandez A, (1991) P67Srf Is a Constitutive Nuclear-Protein Implicated in the Modulation of Genes Required Throughout the G1 Period. Cell Regulation 2: 575-588.
39. Poser S, Impey S, Trinh K, Xia ZG, Storm DR, (2000) SRF-dependent gene expression is required for PI3-kinase-regulated cell proliferation. Embo Journal 19: 4955-4966.
40. Soulez M, Rouviere CG, Chafey P, Hentzen D, Vandromme M, et al. (1996) Growth and differentiation of C2 myogenic cells are dependent on serum response factor. Molecular and Cellular Biology 16: 6065-6074.
41. Schratt G, Weinhold B, Lundberg AS, Schuck S, Berger J, et al. (2001) Serum response factor is required for immediate-early gene activation yet is dispensable for proliferation of embryonic stem cells. Molecular and Cellular Biology 21: 2933-2943.
42. Koegel H, von Tobel L, Schafer M, Alberti S, Kremmer E, et al. (2009) Loss of serum response factor in keratinocytes results in hyperproliferative skin disease in mice. Journal of Clinical Investigation 119: 899-910.
43. Davis FJ, Gupta M, Camoretti-Mercado B, Schwartz RJ, Gupta MP, (2003) Calcium/calmodulin-dependent protein kinase activates serum response factor transcription activity by its dissociation from histone deacetylase, HDAC4- Implications in cardiac muscle gene regulation during hypertrophy. Journal of Biological Chemistry 278: 20047-20058.
44. Heidenreich O, Neininger A, Schratt G, Zinck R, Cahill MA, et al. (1999) MAPKAP kinase 2 phosphorylates serum response factor in vitro and in vivo. Journal of Biological Chemistry 274: 14434-14443.
45. Ronkina N, Menon MB, Schwermann J, Arthur JS, Legault H, et al. Stress induced gene expression: a direct role for MAPKAP kinases in transcriptional activation of immediate early genes. Nucleic Acids Res.
46. Janknecht R, Hunter T, (1997) Convergence of MAP kinase pathways on the ternary complex factor Sap-1a. Embo J 16: 1620-1627.
47. Montagne J, Groppe J, Guillemin K, Krasnow MA, Gehring WJ, et al. (1996) The Drosophila Serum Response Factor gene is required for the formation of intervein tissue of the wing and is allelic to blistered. Development 122: 2589-2597.
48. Arsenian S, Weinhold B, Oelgeschlager M, Ruther U, Nordheim A, (1998) Serum response factor is essential for mesoderm formation during mouse embryogenesis. Embo Journal 17: 6289-6299.
49. McDonald OG, Wamhoff BR, Hoofnagle MH, Owens GK, (2006) Control of SRF binding to CArG box chromatin regulates smooth muscle gene expression in vivo. Journal of Clinical Investigation 116: 36-48.